Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLI-RX-PHL Sublingual Immunotherapy for Grass Pollen Allergy
2024-517524-18-00Phase 3Authorised
- Sponsor
- ROXALL Medizin GmbH
- Start
- Sep 2025
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of phleum pratense allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and grass pollen allergy (4 arms), sponsored by ROXALL Medizin GmbH. Planned start Sep 2025; status: authorised.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2024-517524-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517524-18-00.